Artizan Biosciences, Inc., a biotechnology company creating gut exclusive microbial metalloprotease inhibitors (GEMMi), a new class of transformative precision therapeutics that disrupt chronic inflammatory disease triggers, today announced that it has entered into a multi-year research collaboration with the University Medical Center Utrecht (
